Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 13, 2023
Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analysesElaine Limkin, Pierre Blanchard, Benjamin Lacas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trialsCarine A Bellera, Marina Pulido, Sophie Gourgou, et al.
European Journal of Haematology|February 11, 2021
Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivorsHugo Vachon, Justyna Mierzynska, Mekdes Taye, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 14, 2022
The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trialOrit Kaidar-Person, Catherine Fortpied, Sandra Hol, et al.
European Urology Oncology|November 8, 2025
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized TrialThomas Zilli, Dirk Böhmer, Andreas Roeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialPatrice Carde, Matthias Karrasch, Catherine Fortpied, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Blood|February 14, 2018
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trialAnne-Ségolène Cottereau, Annibale Versari, Annika Loft, et al.
Journal of the National Cancer Institute|July 28, 2021
Side Effects 15 Years After Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925Philip M Poortmans, Henk Struikmans, Peter De Brouwer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2017
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysisLiat Vidal, Anat Gafter-Gvili, Gilles Salles, et al.
Pageof 5